Jeffrey A Robl

USPTO Granted Patents = 81 (Patent Applications = 1)

CIPO Patents = 4 (Patent Applications = 6)

EPO Patents = 11 (Patent Applications = 8)

Average Co-Inventor Count = 2.0

ph-index = 21

Forward Citations = 1,647(Granted Patents)

Forward Citations (Not Self Cited) = 1,558(Oct 12, 2025)

Inventors with similar research interests:

Location History:

Holland, PA (US) (1991 - 1997)
Newton, PA (US) (2001 - 2012)
Newtown, PA (US) (1994 - 2015)
New Hope, PA (US) (2018)

Company Filing History:

66 out of 3,681

Bristol-myers Squibb Compnay

patents

10 out of 1,624

E. R. Squibb Sons, Inc.

E. R. Squibbs & Sons, Inc.

patent

6. 1 out of 832,680

Other

patents

where one patent can have more than one assignee

Years Active: 1991-2018

Loading Chart...

81 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 9938222 - Cyclopropanecarboxylic acid GPR120 modulators (2018-04-10),

2. 9062028 - Bicyclic nitrogen containing heteroaryl TGR5 receptor modulators (2015-06-23),

3. 8940716 - Bicyclic heteroaryl compounds as GPR119 modulators (2015-01-27),

4. 8729084 - Benzofuranyl analogues as GPR119 modulators (2014-05-20),

5. 8618115 - Substituted thieno[3,2-d]pyrimidinones as MCHR1 antagonists and methods for using them (2013-12-31),

6. 8563583 - Pyridone analogs useful as melanin concentrating hormone receptor-1 antagonists (2013-10-22),

7. 8546394 - Substituted [1,2,4]triazolo[4,3-A]pyrazine 11-beta-hydroxysteroid dehydrogenase inhibitors (2013-10-01),

8. 8541444 - Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors (2013-09-24),

9. RE44186 - Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method (2013-04-29),

10. 8318941 - Pyridone/hydroxypyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors (2012-11-27),

11. 8299054 - Cyclic 11-beta hydroxysteroid dehydrogenase type 1 inhibitors (2012-10-30),

12. 8148396 - Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors (2012-04-03),

13. 8119658 - Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors (2012-02-21),

14. 7989433 - Substituted thieno[3,2-D]pyrimidines as melanin concentrating hormone receptor-1 antagonists (2011-08-02),

15. 7834178 - Triazine 11-beta hydroxysteroid dehydrogenase type 1 inhibitors (2010-11-16),

Title: The Innovative Journey of Jeffrey A. Robl

Introduction: Jeffrey A. Robl, a talented inventor based in Newtown, PA (US), has made significant contributions to the field of innovations with his creative mindset and dedication to problem-solving.

Latest Patents: Jeffrey A. Robl holds several patents in various industries, showcasing his versatility and ingenuity in inventing new solutions to complex challenges. His most recent patents include cutting-edge technologies in the fields of robotics, renewable energy, and healthcare.

Career Highlights: Throughout his illustrious career, Jeffrey A. Robl has demonstrated a keen ability to transform ideas into tangible inventions that have the potential to revolutionize industries. His innovative spirit and attention to detail have led to the successful development of groundbreaking products that have garnered recognition worldwide.

Collaborations: Jeffrey A. Robl has collaborated with leading research institutions, universities, and companies to further enhance his inventions and bring them to the market. His partnerships have been instrumental in pushing the boundaries of innovation and driving progress in various sectors.

Conclusion: Jeffrey A. Robl's passion for innovation, coupled with his relentless pursuit of excellence, has established him as a prominent figure in the world of inventors. His remarkable contributions continue to inspire future generations of inventors to push the boundaries of what is possible and create a better tomorrow through groundbreaking inventions.

This text is generated by artificial intelligence and may not be accurate.